Loading
Life sciences · Journal article
Frontiers in Microbiomes · October 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Although the gut microbiome is increasingly recognized as an important regulator of metabolic, immune, and neurophysiological functions, and mitochondrial dysfunction is considered a hallmark of metabolic flexibility, oxidative stress, and resistance to therapy in cancers, the role of microbiome-derived cues and mitochondrial processes in brain tumors remains poorly understood. The Microbiome-Gut-Brain-Mitochondria Axis in Neuro-Oncology provides a framework for understanding metabolism and immunity in neuro-oncology by highlighting this axis and emphasizing its role in glioblastoma. Metabolites produced by the microbiome, including short-chain fatty acids, bile acid metabolites, tryptophan metabolites, and other microbial compounds, have been shown to affect the immune system, barrier function, cellular metabolism, and neural signaling. Mitochondria are capable of functioning as intracellular communication mechanisms that will help to decipher those signals in order to create energy, ROS, calcium communication, biogenesis of mitochondria, quality control, and apoptosis. These processes may contribute to metabolic plasticity in glioblastomas, including glycolytic, oxidative phosphorylation, and amino- and lipid-metabolic adaptations, mitochondrial transfer, adaptation to hypoxia, tumor cell stemness, and immune suppression in the tumor microenvironment. The article also discusses the relationships between microbiome-derived cues, mitochondria, and tumor-associated immune populations. Microbiome-derived and mitochondrial biomarkers, combined with multi-omics approaches, single-cell technologies, spatial biology, artificial intelligence, and new experimental models, may help to identify relevant microbiome-mitochondria signatures. Modulating the microbiome, mitochondria, and combination therapies appears promising for glioblastomas. However, the causative link between microbiome-derived mitochondrial mechanisms and human brain tumors remains unproven. The necessity of prospective and mechanistic studies of the microbiome, mitochondria, metabolism, immunity, and clinical aspects arises.